Stockscreener 앱 받기
9.24
4.15%
-0.40
전일 마감가:
$9.64
열려 있는:
$9.64
하루 거래량:
505.13K
Relative Volume:
0.97
시가총액:
$483.74M
수익:
$57.94M
순이익/손실:
$-151.18M
주가수익비율:
-3.2864
EPS:
-2.8116
순현금흐름:
$-86.56M
1주 성능:
-4.64%
1개월 성능:
+16.81%
6개월 성능:
+0.54%
1년 성능:
+40.64%
1일 변동 폭
$9.03
$9.82
1주일 범위
$9.03
$10.02
52주 변동 폭
$6.16
$11.80
Prothena Corp Plc Stock (PRTA) Company Profile
명칭
Prothena Corp Plc
전화
011-353-1-236-2500
주소
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRTA
Prothena Corp Plc
|
9.24 | 483.74M | 57.94M | -151.18M | -86.56M | -2.8116 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prothena Corp Plc Stock (PRTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-05-27 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-05-27 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-27 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-01-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-04-24 | 개시 | SVB Securities | Outperform |
| 2023-01-27 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-09-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-11-19 | 개시 | JMP Securities | Mkt Outperform |
| 2021-06-18 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-06-08 | 재확인 | Oppenheimer | Outperform |
| 2021-05-26 | 개시 | Citigroup | Buy |
| 2021-02-26 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-02-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-02 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-12-07 | 개시 | H.C. Wainwright | Buy |
| 2020-07-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-11-19 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-05-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-04-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-04-05 | 재확인 | Barclays | Overweight |
| 2017-11-20 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2017-09-29 | 재확인 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-11 | 개시 | Jefferies | Buy |
| 2017-04-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-04-12 | 개시 | Piper Jaffray | Overweight |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-12-21 | 개시 | SunTrust | Buy |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-08-04 | 재확인 | Barclays | Overweight |
| 2016-05-13 | 개시 | Barclays | Overweight |
| 2016-02-19 | 재확인 | Wedbush | Outperform |
| 2016-01-21 | 개시 | Credit Suisse | Outperform |
모두보기
Prothena Corp Plc 주식(PRTA)의 최신 뉴스
Prothena Corp plc updates investors on pipeline progress as neurodegeneration focus deepens - ad-hoc-news.de
Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider - GlobeNewswire Inc.
PRTAProthena Corp Plc Options - Finviz
Price to sales forward of Prothena Corp. Plc – MUN:0PT - TradingView
Enterprise value to revenue forward of Prothena Corporation plc – NASDAQ:PRTA - TradingView
Enterprise value to EBIT forward of Prothena Corporation plc – NASDAQ:PRTA - TradingView
Price to book forward of Prothena Corp. Plc – MUN:0PT - TradingView
Enterprise value to EBITDA forward of Prothena Corp. Plc – MUN:0PT - TradingView
Enterprise value to revenue forward of Prothena Corp. Plc – MUN:0PT - TradingView
Prothena Corp, Parkinson antibody program draws attention for the stock - ad-hoc-news.de
Prothena Corp. Plc Actuals & Estimates (NASDAQ:PRTA) - TradingView
Prothena Corp. Plc Actuals & Estimates (DUS:0PT) - TradingView
Prothena Corp. Plc Actuals & Estimates (SWB:0PT) - TradingView
PRTA Forecast — Price Target — Prediction for 2027 - TradingView
0PT Forecast — Price Target — Prediction for 2027 - TradingView
Prothena Corporation PLC (PRTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Prothena Corporation Plc (NASDAQ:PRTA) About To Shift From Loss To Profit - Moomoo
Prothena Corp plc strategy in focus, shares watched against biotech peers - AD HOC NEWS
Prothena Corporation PLC (PRTA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prothena Corporation PLC (PRTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Prothena Corporation PLC (PRTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Prothena Corporation PLC (PRTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price-Driven Insight from (PRTA) for Rule-Based Strategy - Stock Traders Daily
(PRTA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
PRTA Q1 2026 Earnings: Surprise EPS Beat Driven by Milestone Revenue, Stock Edges HigherDownward Estimate Revision - The Legal Advocate
(PRTA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Penbrook Management LLC's Prothena Corp PLC(PRTA) Holding History - GuruFocus
Prothena (NASDAQ: PRTA) investors approve board, KPMG and executive pay - Stock Titan
Rubric Capital and David Rosen disclose 9.29% stake in Prothena (PRTA) - Stock Titan
Prothena Corp plc stock (IE00B91XRN20): Biotech investor focus amid pipeline updates - AD HOC NEWS
Number of shareholders of Prothena Corp. Plc – DUS:0PT - TradingView
PRTA Stock Price, Quote & Chart | PROTHENA CORP PLC (NASDAQ:PRTA) - ChartMill
William Scully reports 10.27% stake in PROTHENA (NASDAQ: PRTA) - Stock Titan
Prothena Corp. Down Over 9%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk - Moomoo
Earnings Beat: Prothena Corporation plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
Prothena (PRTA) Heavy US$244 Million Annual Loss Tests Bullish Profitability Narratives - Sahm
Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment - Yahoo Finance
Prothena (PRTA) Highlights Progress in Parkinson's Research and Collaborations - GuruFocus
Citizens raises Prothena stock price target on milestone payment By Investing.com - Investing.com UK
Prothena (PRTA) Revises 2026 Cash Outlook and Operating Expenses - GuruFocus
Prothena (NASDAQ:PRTA) Smashes Q1 Estimates on $50 Million Milestone Payment, Shares Steady - ChartMill
Prothena: Q1 Earnings Snapshot - marketscreener.com
Milestone revenue lifts Prothena (NASDAQ: PRTA) cash and pipeline - Stock Titan
Prothena (NASDAQ: PRTA) posts $32.7M Q1 profit and lifts 2026 cash outlook - Stock Titan
A $50M Novo milestone reshaped Prothena’s 2026 cash outlook - Stock Titan
Tranche Update on Prothena Corporation plc's Equity Buyback Plan announced on February 27, 2026. - marketscreener.com
Prothena to Report First Quarter 2026 Financial Results on May 7 - ChartMill
3 Growth Companies Insiders Are Eager To Hold - Sahm
Prothena (NASDAQ:PRTA) Shares Up 5.9%Time to Buy? - MarketBeat
FDA Fast Track granted to Phase 3 drug for ATTR-CM - Stock Titan
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy - The Joplin Globe
Prothena Corp Plc (PRTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Prothena Corp Plc 주식 (PRTA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SCULLY WILLIAM P | 10% Owner |
Jun 11 '26 |
Buy |
8.17 |
125,000 |
1,021,225 |
1,061,000 |
2.64%
자본화:
|
볼륨(24시간):